{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:15Z","timestamp":1761871335062,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.clml.2019.03.031","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T02:31:49Z","timestamp":1554431509000},"page":"e337-e342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study"],"prefix":"10.1016","volume":"19","author":[{"given":"Mari","family":"Morita-Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-0463","authenticated-orcid":false,"given":"Daisuke","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-9508","authenticated-orcid":false,"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.031_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.031_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","article-title":"The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas","volume":"129","author":"Sonnen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.031_bib3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.03.031_bib4","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the\u00a0International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.031_bib5","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.031_bib6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Coiffier","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2019.03.031_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.03.031_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00432-008-0440-0","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)","volume":"135","author":"Kitagawa","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.031_bib9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1349-7006.2009.01167.x","article-title":"Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma","volume":"100","author":"Morito","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2019.03.031_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A\u00a0high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.03.031_bib11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3109\/10428194.2013.850167","article-title":"Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era","volume":"55","author":"Proch\u00e1zka","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.03.031_bib12","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.031_bib13","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.031_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.031_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/1097-0142(19920201)69:3<772::AID-CNCR2820690326>3.0.CO;2-Z","article-title":"Alternating non-cross-resistant chemotherapy for non-Hodgkin lymphoma of intermediate-grade and high-grade malignancy. A pilot study","volume":"69","author":"Hirano","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.03.031_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.031_bib17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.031_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/1043-4666(90)90062-X","article-title":"The molecular basis for the generation of the human soluble interleukin 2 receptor","volume":"2","author":"Rubin","year":"1990","journal-title":"Cytokine"},{"key":"10.1016\/j.clml.2019.03.031_bib19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood.V76.10.1941.1941","article-title":"Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia","volume":"76","author":"Richards","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.031_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood.V72.2.447.bloodjournal722447","article-title":"The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors","volume":"72","author":"Kay","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.031_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","article-title":"T\u00a0regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies","volume":"131","author":"Lindqvist","year":"2010","journal-title":"Immunology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:01Z","timestamp":1761870781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018316641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2152265018316641"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.031","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}